Rockwell Medical Extends Product Purchase Agreement Through 2026 With One of the Largest Dialysis Providers in the United States

WIXOM, Mich.–(BUSINESS WIRE)–$RMTI #EndStageKidneyDisease–Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Amended and Restated Product Purchase Agreement (the “Amended Agreement”) dated September 18, 2023 between the Company and one of the largest dialysis providers in the United States (the “Customer”) has been extended through December 31, 2026. As part of the Amended Agreement, product pricing will be increased for the extended term.

“We are pleased to extend our product purchase agreement with the Customer through the end of this year, and continue to foster our relationship in the hope that we can expand our agreement well beyond 2026,” said Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. “We believe this renewal reflects the critical role that our reliable supply chain and high-quality hemodialysis products play in the Customer’s operations. We are committed, and excited for the opportunity, to strengthen our relationship with the Customer and re-establish a more robust, long-term strategic partnership.”

For more details about this amended and restated products purchase agreement, please reference the Form 8-K filed January 5, 2026.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical’s mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. Rockwell Medical’s products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work^® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & Production in 2024 and 2025, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions. For more information, visit www.rockwellmed.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as, “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “can,” “would,” “develop,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” “look forward to,” “remain confident,” “are determined,” “are committed to,” “are on track,” “are resolute in our vision,” “work to,” “drive towards,” “focused on,” “seeks to” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. Such statements include statements relating to the importance of our reliable supply chain and high-quality hemodialysis products to the customer’s operations and the strengthening of our relationship with the customer and reestablishing a more robust, long term strategic partnership. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical’s SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

Contacts

(248) 432-1362

IR@RockwellMed.com